Novavax Inc (NVAX)
$113.56 11.12 (10.86%)
16:34 EDT NVAX Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 43.34B
PE Ratio -186.16
Volume (Avg. Vol.) 8.31M
Day's Range 105.80 - 117.35
52-Week Range 3.54 - 189.40
Dividend & Yield N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
- From InvestorPlace
- From the Web
With biotech companies, regardless of what drug, therapy or vaccine being worked on, clinical trials are vital and that's certainly the case with NVX-CoV2373 stepping into the second stage. This trial is relevant because it will include testing on humans in age groups deemed highly susceptible to contracting Covid-19 and dying from the illness.
NVAX stock has been among the hottest stocks in 2020, but it still remains a risky investment
NVAX stock appears to be a decent wager in the vaccine sweepstakes despite recent volatility and some insider selling.
Vaccine approval certainly can drive NVAX stock back to new highs after a recent pullback. But risks go beyond vaccine development.
By Ian Cooper
The pandemic shows no signs of slowing, it's time to use any signs of weakness in coronavirus stocks as a buying opportunity.
Novavax has failed at late-stage clinical trials before, but if its COVID-19 vaccine even has 50% efficacy it could open up a huge global opportunity.
In the race to bring a Covid-19 vaccine to market, Novavax just scored a major coup and that's super-bullish for NVAX stock.
Home Depot, Novavax, Rosetta Stone and Penn National Gaming were our top stock trades for Thursday. That said, let's look at the charts now.
Novavax (NVAX) news for Thursday concerning includes the company's stock falling hard on talk of a vaccine for the novel coronavirus.
Novavax looks like a winner with its positive Covid-19 vaccine results. NVAX stock is worth at least 35% more than today based on widespread acceptance of its vaccine.
Investors have reasons to worry yet the markets continue to rally. AAPL, NVAX and NKLA are three hot stocks to trade now.
NVAX stock is one of the hottest biotech stocks in 2020. But it's time for the company to deliver results worthy of its price.
The market went crazy after reports emerged about the safety of Novavax's Covid-19 vaccine. Here's what you need to know about NVAX stock.
Novavax (NASDAQ:NVAX) looks on its way to a credible vaccine. If so, NVAX stock going to $200 by the end of the years seems all but certain.
Novavax has been one of the companies cashing in on the race to find a vaccine against COVID-19. As a result NVAX stock is up over 3,000% year-to-date
There’s no doubting that Novavax offers an exciting new technology for a coronavirus vaccine candidate. However, NVAX stock is a trickier once you look beyond the headlines.
While it’s no guarantee that NVAX stock will be the ultimate winner from a Covid-19 vaccine, investors should pay attention to Novavax.
From Market News Video
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Axonics Modulation Technologies Inc (AXNX), where a total volume of 4,984 contracts has been traded thus far today, a contract volume which is representative of approximately 498,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 85.5% of AXNX's average daily trading volume over the past month, of 582,635 shares..
Navellier RatingsPowered by Portfolio Grader